Inventiva (IVA) Deferred Taxes (2021 - 2025)

Inventiva (IVA) posted quarterly Deferred Taxes of -$646349.0 for Q2 2025, down 756.11% quarter-over-quarter from -$75498.3 in Q4 2022.

Inventiva (IVA) Deferred Taxes (2021 - 2025) Analysis & Trends

Inventiva's Deferred Taxes history runs 3 years deep, the most recent figure standing at -$646349.0 for Q2 2025.

In Q2 2025, Deferred Taxes changed N/A year-over-year to -$646349.0; the TTM figure through Jun 2025 stood at -$773894.5 (changed N/A YoY), while the FY2022 annual figure was -$75498.3, down 399.98% from the prior year.
Deferred Taxes for Q2 2025 stood at -$646349.0, down from -$75498.3 in the prior quarter.
The five-year high for Deferred Taxes was $25167.4 in Q4 2021, with the low at -$646349.0 in Q2 2025.
The 3-year median for Deferred Taxes is -$76356.4 (2022), against an average of -$193473.6.
Peak annual rise in Deferred Taxes reached 399.98% in 2022, while the deepest fall reached 399.98% in 2022.
Inventiva's Deferred Taxes stood at $25167.4 in 2021, then slumped by 399.98% to -$75498.3 in 2022, then plunged by 756.11% to -$646349.0 in 2025.
Business Quant data shows IVA's Deferred Taxes at -$646349.0 in Q2 2025, -$75498.3 in Q4 2022, and -$77214.5 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-137,876.64
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	2.66 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Inventiva	888.89 Mn	888.89 Mn	-	-

Download Data